FDA-Cleared Exoskeleton Expands Mobility for Wheelchair Users with Spinal Cord Injuries

Eve, a self-balancing exoskeleton cleared by the FDA for U.S. commercial use, provides hands-free upright mobility for wheelchair users with spinal cord injuries at any level.

Eve, a self-balancing personal exoskeleton developed by a Paris-based company, received FDA clearance for U.S. commercial use on September 21, 2026. The device enables hands-free upright mobility for individuals with spinal cord injuries at any level, reducing physical strain and improving independence. Users must manually operate its controller, which creates specific eligibility requirements: the device only serves those with spinal cord injuries and the capacity to manage the controller interface.

This clearance represents the first FDA-authorized self-balancing exoskeleton designed for personal mobility in this application. Its mechanism directly addresses a critical barrier for wheelchair users with spinal cord injuries by enabling independent upright positioning without manual assistance. The device’s ability to function as a hands-free system reduces the physical burden of maintaining posture, a major challenge for this population.

For wheelchair users with spinal cord injuries, Eve moves mobility toward practical independence by reducing the energy expenditure needed for basic movement. However, its eligibility restricts access to users who can operate the controller—meaning it does not universally solve mobility barriers. What remains to be seen is whether this clearance will lead to wider adoption among eligible users or if further refinement is needed to address the controller dependency. The claim that Eve is 'the world's first' FDA-cleared self-balancing exoskeleton requires independent verification beyond the source’s statement.

Source: HumanProgress